EMERGING EPO AND EPO RECEPTOR REGULATORS, AND SIGNAL TRANSDUCERS

Running Head: EPO / EPOR response circuits

David Kuhrt¹ and Don M. Wojchowski¹,²,³

¹Molecular Medicine Division, Maine Medical Center Research Institute, Scarborough, ME
²Tufts University School of Medicine, Boston, MA

³Corresponding Author:
Don M. Wojchowski
Director, Center of Excellence in Stem & Progenitor Cell Biology and Regenerative Medicine
Maine Medical Center Research Institute
Scarborough, Maine 04074
Professor of Medicine
Tufts University School of Medicine
Boston, MA 02111
wojchd@mmc.org
207-396-8258

Text word count: 2231
Abstract word count: 80
Number of Figures:  1
Number of references: 93
Abstract

As essential mediators of red cell production, erythropoietin (EPO) and its cell surface receptor (EPOR) have been intensely studied. Early investigations defined basic mechanisms for Hypoxia-Inducible Factor induction of EPO expression, and within erythroid progenitors EPOR engagement of canonical JAK2/STAT5, RAS/MEK/ERK and PI3K pathways. Contemporary genetic, bioinformatic, and proteomic approaches continue to uncover new clinically relevant modulators of EPO and EPOR expression, and EPO’s biological effects. This Spotlight review highlights such factors and their emerging roles during erythropoiesis and anemia.
Introduction

Early parabiotic experiments with anemic and nephrectomized rats predicted the existence of erythropoietin (EPO) as a blood-borne kidney-derived activator of erythropoiesis. Evidence that EPO occurs as a unique glycoprotein hormone was further advanced via arduous fractionations and bioassays of urinary proteins from anemia patients. The purification, partial sequencing and cloning of erythropoietin have led to the generation of rhEPO (recombinant human EPO) (and derivatives) for the treatment of anemia associated with chronic kidney disease (CKD), chemotherapy, and low-risk myelodysplastic syndrome (MDS). The subsequent discovery of EPO's receptor (EPOR) as a plasma membrane single-pass homodimer elevated the EPO/EPOR system as a paradigm for hematopoietic cytokine receptor action. The EPOR, for example, was among the first discovered to associate with a Janus kinase, to transduce signals via trans-membrane conformational mechanisms, and to be causally associated with polycythemia. EPO's clinical and scientific successes have prompted in-depth investigations into EPO/EPOR biology. This review focuses on intriguing advances in understanding the regulation of EPO and EPOR expression, and the nature of novel EPO/EPOR signals that regulate erythroid progenitor cell (EPC) development. EPO also has been reported to exert survival, proliferative and/or developmental effects in a wide range of non-hematopoietic tissues. In such cell types, however, EPOR protein expression (including cell surface levels) can be nominal, thereby complicating interpretations for direct versus indirect effects. Nonetheless, incisive EPOR loss-of-function approaches have revealed interesting EPO effects in cardiomyocyte mitochondrial biogenesis, retinal cell cytoprotection, melanoma cell survival and adipogenesis. This broad area of investigation, however, lies beyond the scope of the present report.
**EPO expression**

The nature of rare Epo-producing cells first is becoming more clearly defined. During primitive erythropoiesis, studies using an *Epo* gene GFP knock-in mouse indicate predominant *Epo* expression by neural crest and neuroepithelial cells. Tracking studies of myelin protein-zero marked peripheral neural cells demonstrate that Epopos embryonic neural crest fibroblasts migrate to the kidney, and perinatally reside within peritubular interstitia. Renal fibrosis due to ureteral obstruction can promote transdifferentiation of *Epo*high fibroblasts to *Epo*low myofibroblasts. *Epo* levels in myofibroblasts can be increased, however, via neurotropin or dexamethasone dosing. During stress erythropoiesis, *Epo* expression can also be induced in liver, as well as bone marrow osteoblasts as demonstrated upon von Hippel-Lindau Factor (VHL) inactivation.

New insight has also been gained into *EPO* gene regulation. Early investigations of hypoxia-induced *EPO* expression established important roles for a downstream *EPO* enhancer (E-3’) as a binding site for hypoxia-inducible factor (HIF) and hepatocyte nuclear factor 4 (HNF4) transcriptional regulators. In vivo studies in mice with a GFP-marked *Epo* allele demonstrate that E-3’ deletion results in embryonic and neonatal anemia. In juvenile and adult kidney, however, *Epo* production is unexpectedly regained in the absence of E-3’, while hepatic Epo production continues to depend upon E-3’ effects. For renal *EPO* production, this raises new questions concerning activation mechanisms.

Among HIF1α, -2α and -3α, HIF2α has been defined as a prime component of an *EPO* gene activating complex. New insight into HIF2α regulation (beyond requisite heterodimerization with HIFβ/ARNT) has also been gained. Hif2α’s translation first has been shown to be suppressed via iron response element binding protein Irp1 (in a knockout mouse model), thus connecting iron levels to Hif2α/HIFβ-regulated *Epo* gene expression. HIF2α’s activity is also modulated by lysine acetylation and deacetylation via CREB-binding protein (CBP) and sirtuin (SIRT), respectively.
acetylation, acetyl-CoA levels during stress erythropoiesis can become physiologically limiting. Specifically, Hif2α’s acetylation, CBP association, and enhanced activity have been shown in an Acss2-KO model to depend upon acetyl-CoA synthetase-2.33 Moreover, acetate supplementation in vivo elevates Epo levels as well as hematocrits in hemolytic, partial nephrectomy CKD and Kit mutant models. The turnover of HIFs is promoted via hydroxylation by prolyl 4-hydroxylases (PHDs), and ubiquitination by VHL.30 Notably, several PHD inhibitors have been developed as HIF stabilizers to enhance EPO and erythrocyte production (e.g., Roxadustat (FibroGen/Astellas), AKB-6548 (Akebia Therapeutics), GSK1278863 (GlaxoSmithKline)).34

EPO receptor expression, and EPOR signal modifiers

The expression of EPO’s receptor is stringently regulated, and low level (~1,100 EPORs per primary human EPC, ~300 per late-stage erythroblast as determined via 125I-EPO binding studies).35 At the EpoR locus, Gata1,36 Sp137 and Scl/Tal138 stimulate transcription but additional regulators are not well defined. For EPOR trafficking, certain new insights have been gained. Over-expression studies in murine myeloid 32D cells suggest ligand-independent EpoR turnover, with replenishment from a predicted large intracellular pool.39 For the endogenous EPOR, however, studies in human UT7epo and/or primary EPCs demonstrate substantial up-modulation of cell surface EPORs when EPO is limited, marked down-modulation upon EPO exposure, and only modest intracellular EPOR pools.40 During EPOR endocytosis, coordinated roles for p85-α (PI3 kinase regulatory subunit), ubiquitinated Casitas B-lineage lymphoma (Cbl) and Epsin1 have been described.41,42 In UT7epo cells, β-transducin repeat containing E3 ubiquitin ligase (β-TRCP) subsequently promotes EPOR degradation.43 Dynamic down-modulation of low-level EPOR cell surface expression emphasizes a need for cautious interpretation of apparent EPOR levels, and the use of high-specificity reagents.17,40

Several new EPOR interacting factors have been described. Proteomic analyses of biotin-EPO/EPOR complexes have identified transferrin receptor 2 (TFR2) as an EPOR partner.44 In
UT7epo cells, TFR2 facilitates EPOR processing and transport to the cell surface. In primary human EPCs, TFR2 knockdown decreased hemoglobinized cell formation, and increased numbers of early stage EPCs. EPCs from $Tfr2^{-/-}$ mice exhibit decreased EPO-sensitivity, and CFUe formation. During iron deficiency, Tfr2 also acts to balance erythrocyte production with available iron. Beyond its established roles in hepatocyte iron transport, Tfr2 also therefore modulates EPO-dependent erythropoiesis. In addition, phospho-proteomic analyses have identified the integral plasma membrane protein regulator of human erythroid cell expansion (RHEX) as a new EPOR-associated factor. In UT7epo cells, RHEX co-IP's with EPOR/JAK2 complexes, and its tyrosine phosphorylation is strongly induced by EPO. In primary EPCs, RHEX exhibits stage-specific expression, and its knockdown attenuates ERK1/2 activation as well as late-stage human erythroblast development. Interestingly, RHEX is not represented among rat, mouse or lower vertebrates.

Transferrin receptor 1 (TFR1) also can modulate EPOR signaling. Specifically, Tfr1 ligation by polymeric-IgA1 (p-IgA1) in murine erythroblasts increases EPO/EPOR-dependent MAPK and PI3K signaling. This occurs in the absence of transferrin binding, but depends upon a Tfr1 endocytic motif. In a knock-in model, human p-IgA1 enhances recovery from anemia due to 5-fluorouracil, hypoxia and hemolytic anemia. p-IgA1 also binds CD89, an Fc-α receptor and suppressor of inflammatory cytokine production. By speculation, p-IgA1 might also aid stress erythropoiesis by lessening inflammation, a mechanism implicated for an Activin receptor-IIA ligand trap as a new anti-anemia agent.

**EPOR signal transduction via RAS/RAF/MEK/ERK circuits**

As demonstrated in primary human EPCs, balanced activation of RAS pathways is required for effective EPO-dependent erythroblast formation. In mouse models, deletion of K-Ras (but not H-Ras or N-Ras) generates severe anemia, and compromises EPO-dependent fetal liver EPC development. Activated K-Ras$^{G12D}$ likewise induces severe anemia in due to ineffective fetal
erythropoiesis, and persistently stimulates Erk1/2, Akt and Stat5. Of clinical interest, inhibition of RAS farnesylation by Tipifarnib decreases polycythemia vera BFUe hyperproliferation. During erythropoiesis, RAS is also regulated by newly emerging GTP/GDP exchange factors. One is the Ras-GTPase activating protein Rasa3 which when mutated in Scat mice leads to anemia and thrombocytopenia. A second is Neurofibromin (Nf1), for which mutations have been associated with juvenile myelomonocytic leukemia, including anemia due to limited EPC differentiation.

Regulation of RAS-modulated targets also is important for EPO-dependent erythropoiesis. C-Raf deletion results in embryonic anemia. And in β-thalassemia proerythroblasts, phospho-C-Raf levels correlate with increased ERK activation. Mek2 is dispensable for mouse development, implicating prime roles for Mek1 in Erk1/2 signaling. In mice expressing a truncated EpoR-HM allele, pharmacological inhibition of Mek reverses stage-specific EPC differentiation defects, while in mice with somatic inactivation of Nf1, Mek1/2 inhibition decreases splenomegaly and enhances erythropoiesis. For ERKs, Erk1- mice exhibit heightened splenic erythropoiesis and hematocrits.

RAS-like GTPase’s can also regulate EPO-dependent EPC formation. As a new EPO/EPOR target gene and Roco family GTPase, malignant fibrous histocytoma-amplified sequences with leucine-rich tandem repeats 1 (MASL1) supports C-RAF/MEK/ERK activation and primary human erythroblast development. As RHO family GTPase’s, RACs also regulate EPC development and erythroblast enucleation. In 32D-EpoR and UT7epo cells, EPO rapidly activates RAC1, implicating possible EPO/EPOR regulation of RACs. In oncology contexts, as new inhibitors of RAS and RAS-like factors are developed, their potential negative effects on erythropoiesis therefore should be evaluated.

EPO/EPOR cytoprotective circuits
EPO’s best-known effects are cytoprotective. Koulnis et al. have described EPO’s slow yet persistent down-modulation of proapoptotic Bcl2-like 11 (Bim) in murine splenic EPCs. Prior studies in HCD57 cells and primary murine EPCs also demonstrated EPO-induced Bim phosphorylation, and proteasomal degradation. Inhibition of Bim therefore represents one EPO-induced EPC survival mechanism. Post EPO dosing, Bcl-xL levels in splenic EPCs transiently increase, and in 32D-EPOR cells Bcl-xL is an EPO/EPOR/STAT5 target gene. These latter EPO effects, however, are not observed in CFUe-like murine bone marrow EPCs, and EPO can efficiently cytoprotect Bclx-KO EPCs. Important questions therefore arise concerning possible additional mediators of EPO/EPOR cytoprotection.

Via gene profiling of murine bone marrow EPCs, an intracellular Spi2A serpin has been identified as a new EPO/EPOR/JAK2/Stat5 target, and cytoprotective factor. Spi2A inhibits B- and L-Cathepsins, which when leached from damaged lysosomes can trigger apoptosis. Spi2A-KO mice exhibit compromised EPO-induced EPC formation, and worsened anemia due to hemolysis or irradiation. Spi2A further cytoprotects erythroblasts against ROS, an effect that is phenocopied by a Cathepsin-B inhibitor. Pharmacologically, selective cathepsin inhibitors therefore might act to limit cell loss due to oxidant damage in thalassemia and/or sickle-cell EPCs. During stress erythropoiesis, FasL/Fas levels can also substantially modulate murine splenic EPC survival. In human EPC’s, TRAIL may be a more potent pro-apoptotic TNF, and FASL may support caspase-dependent late differentiation events. As further illustrated by recent gene profiling studies of human and murine EPCs, complexities can exist in erythroid regulator utilization among species (and erythroid tissues) that require reconciliation.

Additional emerging EPO response circuits

In a context of erythroid neoplasia, JAK2 hyperactivation due to a V617F mutation (within an inhibitory pseudokinase domain) is a frequently contributing factor. Polycythemia vera V617F EPCs can
develop in the absence of EPO, although at lower efficiencies. In a Ba/F3 cell model, JAK2V617F’s transforming potential also is promoted by EPOR (or MPL) expression. For JAK2 R867Q or S755R/R938Q mutations (as associated primarily with thrombocytosis), however, transformation is supported by MPL and not the EPOR. These findings implicate selective EPOR (and MPL) interactions with mutated JAK2 alleles in a context of myeloproliferative disease. JAK2’s degradation interestingly has been demonstrated to involve VHL-mediated ubiquitination. This is illustrated in Chuvash polycythemia in which the VHL mutation R200W alters properties of VHL-SOCS1 E3 ligase complexes, and limits activated phospho-JAK2 turnover.

While EPO/EPOR effects at large require JAK2, supporting roles for Src family kinases also are emerging. Murine EPCs deficient in Lyn exhibit diminished EPO-dependent erythroblast formation. And Src, but not Jak2, may mediate post-translational modification of Cbl, a ubiquitin ligase which promotes EPOR down-modulation (as studied in F-36P cells). Mouse KO models additionally have revealed non-redundant Stat5-independent roles for phospholipase-cy1 (Plc-γ1) in promoting EPOR/Jak2 signals for EPC development. In oncology contexts, promising inhibitors of SRC are being developed that additionally can affect Plc-γ1 and/or RAS circuits. For these agents, potential compromising effects on erythropoiesis also should be considered.

Via EPOR/Jak2/Stat5 signaling, EPO can also induce cytokine expression by EPCs, with the C1q/TNF cytokine family member Erythroferrone (ERFE/Ctrp-15) as a new example. Specifically, ERFE has been discovered to act on hepatocytes to suppress Hepcidin production, thereby lessening Hepcidin’s inhibitory effects on iron efflux from enterocytes, hepatocytes and macrophages. Following phlebotomy, ERFE expression is heightened, with ERFE-KO mice exhibiting delayed recovery from blood loss induced anemia. By comparison, disruption of ERFE in beta-thalassemia mice diminishes iron overload. ERFE modulation therefore has therapeutic potential for balancing systemic iron levels. Unexpectedly, EPO also has been shown to exert effects on pluripotent hematopoietic progenitor cells. Specifically, EPO at elevated levels can alter the transcriptomes of
multi- and bi-potent progenitors.\textsuperscript{91} This generates lineage bias, and increases erythroid output while decreasing myelopoiesis.\textsuperscript{91} EPO therefore may guide EPC differentiation, as previously implicated in studies of EPO/EPOR-stimulated Akt phosphorylation of Gata1.\textsuperscript{92} Such EPO actions might contribute to rhEPO’s enhancement of erythroid recovery following allogeneic transplant.\textsuperscript{93}

\textit{Summary}

Within EPO and EPOR circuits, important new components are being revealed. Several regulate endogenous \textit{EPO} expression (Fig-1A). Apo-IRP1 inhibits \textit{Hif2α} transcript translation,\textsuperscript{31} while iron reverses this effect, heightening HIF2α and EPO levels. Pharmacologically, PHD inhibitors that stabilize HIF2α can likewise increase EPO expression,\textsuperscript{34} as does acetate supplementation via enhancement of Hif2α acetylation during stress erythropoiesis.\textsuperscript{33}

Within EPCs, EPOR activity unexpectedly can be augmented by interactions with several plasma membrane proteins (Fig-1B). TRF2 acts via association with EPOR complexes, while Tfr1 is engaged upon p-IgA1 ligation, with each bolstering EPC formation.\textsuperscript{44,48} This ties two iron importers to EPOR’s effects. In addition, the novel hEPC protein RHEX associates with the hEPOR, enhances ERK1/2 activation, and supports erythroblast development.\textsuperscript{47}

Important downstream EPOR signal transducers also are being discovered (Fig-1C). Within a central RAS/MEK module, these include MASL1,\textsuperscript{63} Rasa\textsuperscript{56} and Neurofibrin,\textsuperscript{57} which act to balance ERK1/2 signaling and EPC production. For EPC cytoprotection, an EPO-induced Spi2A serpin and small molecule inhibitors of leached lysosomal cathepsins have emerged that lessen ROS-associated damage. Pro-erythropoietic actions of Akt, Plc-γ1 and Src family kinases also are being more clearly defined. Finally, EPO is proving to exert guiding effects on early hematopoietic progenitors\textsuperscript{91} pointing to new EPO target populations (and indicating an ability of EPO to affect cells harboring few EPORs). High merit therefore persists for continued investigations of novel EPO/EPOR action mechanisms.
AUTHOR CONTRIBUTIONS: Each author (D Kuhrt and DM Wojchowski) contributed in substantial ways to review concepts, and construction.

CONFLICT OF INTEREST DISCLOSURE: The authors declare no competing financial interests.

ACKNOWLEDGEMENTS: Support for work herein was provided by NIH R01 HL044491 (DMW), NIH R01 DK089439 (DMW) and NIH F32 HL120596 (DK).

References


FIGURE LEGEND

Figure 1. Emerging EPO, and EPOR regulators, and action circuits.  

A) Regulators of EPO expression in renal peritubular interstitial fibroblasts: During embryogenesis, neural tissue derived EPOpos protein-zero pos fibroblasts occupy interstitial peritubular sites within the neonatal kidney. Renal damage and fibrosis can convert these cells to EPO low myofibroblasts (upper sub-panels).24 Within EPOpos interstitial fibroblasts, EPO production is modulated in part by HIF2α, which itself is regulated at multiple levels. Iron reverses Apo-IRP inhibition of HIF2α translation.31 HIF2α turnover is promoted by VHL and PHDs,30 and pharmacological inhibitors of PHDs stabilize HIF2α.34 During stress erythropoiesis, acetate supplementation further can enhance HIF2α complex acetylation, activity and EPO production via an Acss2-CBP circuit.33

B) Modulation of EPOR signaling by interacting plasma membrane proteins: TFR2 associates with the EPOR, and can modulate its trafficking.44 Upon p-IgA1 ligation, Tfr1 also can enhance EPOR signaling.48 RHEX also associates with the hEPOR, and promotes EPO-dependent human erythroblast formation.47

C) Recently defined EPO/EPOR signal transduction circuits: Newly discovered EPO/EPOR response genes include ERF, Spi2A and MASL1. As a secreted TNF-related cytokine, ERF complements a circuit between EPO action, and regulation of systemic iron levels.69 By inhibiting leached lysosomal cathepsins, Spi2A cytoprotects erythrobasts against consequences of oxidative damage.71 MASL1 acts within a central RAS/MEK/ERK circuit,63 together with RHEX, to reinforce ERK1/2 activation.47 Further dynamic balancing of essential RAS/MEK/ERK signals (and of EPC formation) occurs via RAS down-modulation by Rasa356 and Nrf1.57 Pro-erythropoietic effects also are being established for Akt, Plc-γ1, Lyn and Src kinases. Akt can affect erythroid development via serine phosphorylation of Gata1,92 while Lyn and Src can act to enhance EPO/EPOR activated growth/development signals,83,84 and to modulate Cbl’s E3 ligase effects on EPOR turnover.74,75 For each of these EPO/EPOR signal transducers, their engagement and actions appear to become especially important during anemia and/or stress erythropoiesis.
Emerging EPO and EPO receptor regulators, and signal transducers

David Kuhrt and Don M. Wojchowski